Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 9/20 | 0.58 |
| ▸ | PRMT1 | Q99873 | 9/20 | 0.58 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.49 |
| ▸ | HRH1 | P35367 | 3/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.43 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29786357 | 1.00 | CARM1 (0.58) | CARM1PRMT1CSNK2A1HRH1MCHR1 | |
| SCHEMBL29786600 | 0.98 | CARM1 (0.61) | CARM1PRMT1CSNK2A1HRH1MCHR1 | |
| SCHEMBL20472407 | 0.98 | CARM1 (0.61) | CARM1PRMT1CSNK2A1HRH1MCHR1 | |
| SCHEMBL23004969 | 0.96 | CARM1 (0.55) | CARM1PRMT1CSNK2A1HRH1MCHR1 | |
| SCHEMBL30856498 | 0.92 | CARM1 (0.50) | CARM1PRMT1CSNK2A1HRH1SLC6A2 | |
| SCHEMBL23761234 | 0.92 | CARM1 (0.50) | CARM1PRMT1CSNK2A1HRH1SLC6A2 | |
| SCHEMBL34462788 | 0.86 | CARM1 (0.59) | CARM1PRMT1CSNK2A1HRH1MCHR1 | |
| SCHEMBL29786402 | 0.84 | KAT2B (0.49) | CARM1PRMT1CSNK2A1HRH1SLC6A2 | |
| SCHEMBL16814992 | 0.84 | KAT2B (0.49) | CARM1PRMT1CSNK2A1HRH1SLC6A2 | |
| SCHEMBL21486437 | 0.83 | HRH1 (0.53) | CARM1PRMT1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-03-06 | — | — | US | disclosed |
| US-12157733-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-03 | — | — | US | disclosed |
| US-20220315580-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-06 | — | — | US | disclosed |
| US-11440913-B2 | Aminoimidazopyridazines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-13 | — | — | US | disclosed |
| EP-3704118-B1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-01-12 | — | — | EP | disclosed |
| EP-3580220-B1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-11-17 | — | — | EP | disclosed |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
| EP-3704118-A1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20200277296-A1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-03 | — | — | US | disclosed |
| WO-2018148626-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-08-16 | — | — | WO | disclosed |
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1241176-A1 | Purine derivatives for the treatment of ischemia | Pfizer Products Inc. (US) | 2002-09-18 | — | — | EP | disclosed |
| CN-1330629-A | Novel 2-akoxybenzylamine derivatives and their use as medicines for treating schizophrenia | PF MEDICAMENT (FR) | 2002-01-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, TBXA2R | CARM1 4344/4885PRMT1 3767/4885CSNK2A1 3046/4885 |
| US-11440913-B2 | Aminoimidazopyridazines as kinase inhibitors | RIPK1, RIPK4, RIPK3 | CARM1 730/4885PRMT1 583/4885CSNK2A1 322/4885 |
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | CARM1 956/4885PRMT1 548/4885CSNK2A1 472/4885 |
| US-20220315580-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | CARM1 956/4885PRMT1 548/4885CSNK2A1 472/4885 |
| US-12157733-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | CARM1 956/4885PRMT1 548/4885CSNK2A1 472/4885 |
| US-20200277296-A1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | RIPK1, RIPK4, RIPK3 | CARM1 730/4885PRMT1 583/4885CSNK2A1 322/4885 |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | CARM1 960/4885PRMT1 480/4885CSNK2A1 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.